Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-5334 Dosing and Food Interaction Study
NCT01384188Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ONO-5334 in postmenopausal osteoporosis (2 cohorts), sponsored by Ono Pharmaceutical. Primary endpoints: Urine C-terminal telopeptide of type I collagen at Day 5, Area Under the Curve at Day 1 and 1 more. Started Jun 2011; status: completed.
02
Drugs
ONO-5334
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01384188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01384188.